MEDPLUS
Medplus Health
Each stock's 10,000-path forecast, rendered as light.
Medplus Health (MEDPLUS) Stock Analysis & Case Study
Is MEDPLUS a good buy? The data-driven verdict.
Medplus Health (MEDPLUS) trades at ₹833,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 25/100.
On the numbers, Medplus Health (MEDPLUS) high-risk on the numbers, a Downstox Snapshot Score of 25/100, weighing expensive at 45.6× earnings, ROE of 11.8%, a 59% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
MEDPLUS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is MEDPLUS overvalued? MEDPLUS P/E vs its sector
MEDPLUS's P/E of 45.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers.
MEDPLUS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of MEDPLUS history (11%/yr drift, 30%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MEDPLUS 2027 | ₹613 | ₹902 | ₹1,321 | +7% |
| MEDPLUS 2028 | ₹560 | ₹959 | ₹1,639 | +14% |
| MEDPLUS 2029 | ₹524 | ₹1,020 | ₹1,955 | +21% |
| MEDPLUS 2030 | ₹511 | ₹1,090 | ₹2,326 | +29% |
| MEDPLUS 2031 | ₹496 | ₹1,155 | ₹2,728 | +37% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MEDPLUS goes up, or doubles?
The bull case for MEDPLUS
- Medplus Health is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,955.
The bear case & risks
- A rich 45.6× P/E leaves a thin margin of safety if growth slows.
- Return on equity is a soft 11.8%, capital efficiency trails higher-quality peers.
- A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹524.
MEDPLUS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years MEDPLUS compounded at 11%/year with annualized volatility of 30%. That volatility implies a 1-year 80% range of ₹613–₹1,321, the honest backbone behind any single price target.
MEDPLUS price forecast, the full 60-month probability fan
MEDPLUS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MEDPLUS hits common targets within the simulated horizon?
Full multi-horizon detail on the MEDPLUS price target & forecast page.
MEDPLUS Piotroski F-Score: 3/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. MEDPLUS scores 3/9,weak on the financial-strength checks.
MEDPLUS MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy MEDPLUS with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.0% | 2.9× |
| ZerodhaCHEAPEST | 29.3% | 3.4× |
| DhanCHEAPEST | 29.3% | 3.4× |
Compare every broker on the MEDPLUS MTF page.
MEDPLUS vs peers,sector comparison
About Medplus Health: sector, index & market-cap context
Medplus Health (MEDPLUS) is a small-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹10,005 Cr. See more Nifty 200 stocks.
How the MEDPLUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Medplus Health's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MEDPLUS analysis, FAQs
Is Medplus Health (MEDPLUS) a good buy?
On the numbers, Medplus Health (MEDPLUS) high-risk on the numbers, a Downstox Snapshot Score of 25/100, weighing expensive at 45.6× earnings, ROE of 11.8%, a 59% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MEDPLUS overvalued or undervalued?
MEDPLUS trades at 45.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the MEDPLUS share price target for 2031?
MEDPLUS's probability-weighted 2031 median target is ₹1,155, with an 80% range of ₹496–₹2,728 (10,000-path Monte-Carlo).
What is the probability MEDPLUS doubles in 5 years?
The modelled probability of MEDPLUS reaching ₹1,689 (2×) within 5 years is 29%.
What is the bull case for MEDPLUS?
Medplus Health is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in MEDPLUS?
A rich 45.6× P/E leaves a thin margin of safety if growth slows. Return on equity is a soft 11.8%, capital efficiency trails higher-quality peers. A low Piotroski F-Score of 3/9 flags weaker financial health this cycle, worth understanding why before committing.